EnVivo Pharmaceuticals Announces Appointment of Deborah Dunsire, M.D., as President and Chief Executive Officer

  EnVivo Pharmaceuticals Announces Appointment of Deborah Dunsire, M.D., as
  President and Chief Executive Officer

    Industry Leader to Direct Company Growth, Commercialization of Phase 3
 Programs in Alzheimer’s Disease and Schizophrenia, and Expansion of Diverse
                                 CNS Pipeline

Business Wire

WATERTOWN, Mass. -- July 11, 2013

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of
novel therapies for central nervous system (CNS) diseases, today announced the
appointment of Deborah Dunsire, M.D., as president and chief executive
officer. She also joins the company’s board of directors. Dr. Dunsire,
formerly president and chief executive officer of Millennium: The Takeda
Oncology Company, brings more than 25 years of scientific, clinical,
operational and commercial experience, and proven leadership in the biological
and pharmaceutical industry.

Dr. Dunsire served as president and chief executive officer of Millennium
Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005
to 2013. During that period, she transformed the company into a biotechnology
industry leader by focusing R&D, driving the development pipeline, fostering a
culture of employee engagement and increasing the commercial mindset across
the organization to enhance the commercial success of marketed products. The
company was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8
billion – one of the largest biotech acquisitions at that time – and became
Millennium: The Takeda Oncology Company. Dr. Dunsire was the first woman
appointed to Takeda’s board of directors.

“Deborah’s ability to build a fully integrated biopharmaceutical company with
an award-winning culture of innovation and successfully commercialize
late-stage programs while developing a leading research pipeline is
unparalleled,” said Stephen Knight, M.D., chairman of the EnVivo board of
directors and president of Fidelity Biosciences. “She joins EnVivo at a
transformative point in the company’s evolution, as our lead product,
EVP-6124, is in Phase 3 clinical trials in schizophrenia and will enter a
Phase 3 clinical trial in Alzheimer’s disease later this year. We are excited
to work with Deborah to build EnVivo toward global CNS leadership.

I thank Robert Weisskoff, Ph.D., for his exceptional leadership as interim
chief executive officer as he resumes his prior role as a member of the
company's board of directors.”

“CNS diseases, including Alzheimer’s disease and schizophrenia, take a
devastating toll on patients, families and the health care system,” said Dr.
Dunsire. “EnVivo’s late-stage lead product candidate and broad pipeline of
promising clinical programs present a unique and compelling opportunity to
develop new therapies with the potential to make a dramatic impact on
patients’ lives. I am looking forward to working with the EnVivo team to
purpose-build a biopharmaceutical company focused on transforming the CNS
treatment landscape.”

Prior to leading Millennium, Dr. Dunsire led the Novartis U.S. Oncology
Business, playing a critical role in the broad development and successful
launch of a number of products. Over 10 years, she increased the North
American oncology revenues from $50 million to more than $2.2 billion. She
served on the U.S. Pharmaceutical Executive Committee at Novartis. Dr. Dunsire
is currently a board member of Allergan, Inc., the Biotechnology Industry
Organization (BIO), Museum of Science (Boston), Massachusetts General Hospital
Research Advisory Council, CancerCare (New York) and the Gabrielle's Angels
Foundation for Cancer Research. She has received numerous awards, including
the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare
Businesswomen’s Association’s “Woman of the Year”, the 2011 MassBIO Innovator
Award and the 2013 Boston CEO Conference Lifetime Achievement award. Dr.
Dunsire received her medical degree from the University of Witwatersand,
Johannesburg, South Africa.

About EVP-6124

The lead compound in EnVivo’s alpha-7 agonist program, EVP-6124, is a
selective, potent, brain penetrant, oral compound that offers a novel
mechanism of action - it enhances synaptic transmission in the brain and acts
as a co-agonist in combination with Acetylcholine (ACh) to enhance cognition.
By sensitizing the alpha-7 receptor, EVP-6124 makes it possible for smaller
amounts of naturally occurring ACh to be effective in activating the A7
receptor. This mechanism could potentially alleviate the undesirable side
effects caused by other systemic compounds, which are dose-limited by toxic
side effects.

EVP-6124 is in Phase 3 clinical development as a potentially long-term
treatment to restore and improve cognitive function with sustained effect in
Alzheimer’s disease and schizophrenia.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, Inc. and its subsidiaries (“EnVivo Pharmaceuticals” or
“EnVivo”) are dedicated to discovering and developing small molecule
therapeutics for disorders of the central nervous system (CNS). EnVivo
Pharmaceuticals, Inc., based in Watertown, Mass., is a privately held company
working to convert its broad pipeline into a range of CNS therapies that
leverage novel mechanisms of action by altering the progression of disease and
providing improvement in cognitive and overall function. For more information
about EnVivo, visit www.envivopharma.com.


Pure Communications Inc.
Kristie Wallis, 646-320-3845
Press spacebar to pause and continue. Press esc to stop.